Related Experiment Videos
Interferons and interferon inhibitory activity in disease and therapy
Kailash C Chadha1, Julian L Ambrus, Wlodzimierz Dembinski
1Department of Molecular & Cellular Biology, Roswell Park Cancer Institute, State University of New York at Buffalo, Buffalo, New York 14203, USA.
Experimental Biology and Medicine (Maywood, N.J.)
|March 27, 2004
Summary
Interferon resistance, seen in cancer and viral infections, involves mechanisms that block interferon's action. Researchers are investigating ways to overcome these defenses and boost natural interferon production.
Area of Science:
- Immunology
- Oncology
- Virology
Background:
- Interferon (IFN) resistance is a key factor in diseases like cancer, AIDS, lupus, and Wegner's granulomatosis.
- Some conditions exhibit reduced IFN production alongside resistance, suggesting a defense mechanism by pathogens or cancer cells.
- The interference with the IFN system is viewed as a host-defense evasion strategy.
Purpose of the Study:
- To identify and characterize the mechanisms of interferon resistance.
- To explore strategies for reversing these inhibitory effects.
- To investigate methods for enhancing endogenous interferon production.
Main Methods:
- Identification and isolation of IFN resistance factors.
- Chemical structure analysis of novel IFN inhibitory proteins.
- Investigation of prostaglandin E2 and cAMP phosphodiesterase roles in IFN inhibition.
- Studies aimed at reversing inhibitory effects and enhancing IFN production.
Main Results:
- Four key IFN resistance factors have been identified.
- These include free IFN-alpha/beta type 1 receptors, a novel IFN inhibitory protein, prostaglandin E2, and high cAMP phosphodiesterase levels.
- These factors interfere with IFN production and signaling.
Conclusions:
- Understanding IFN resistance mechanisms is crucial for treating neoplastic disorders, viral infections, and autoimmune diseases.
- Reversing these resistance mechanisms and boosting IFN production holds therapeutic potential.
- Ongoing research focuses on developing strategies to overcome IFN resistance.